Litigation
Apr. 17, 2014
University of California wants slice of prostate cancer drug profits
A San Francisco County Superior Court lawsuit alleges pharmacy company Medivation Inc. screwed the University of California out of millions when the company broke a 2005 licensing agreement to use a molecular compound for a cancer drug.
Daily Journal Staff Writer
SAN FRANCISCO- Treating prostate cancer has been a lucrative business for San Francisco-based biopharmaceutical company Medivation Inc., but the University of California now wants what it sees as its fair share of the profits. A newly filed lawsuit alleges Medivation deprived the university of millions when the company broke a 2005 licensing agreement to use a molecular compound for a cancer drug.
&q...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In